Latest Breaking News On - Sarepta therapeutics inc - Page 9 : comparemela.com

DexCom, Inc., v. Abbott Diabetes Care, Inc.: Federal Circuit Finds Forum Selection Clause Does Not Bar IPR Proceedings Based on Contract Interpretation | Haug Partners LLP

DexCom, Inc., v. Abbott Diabetes Care, Inc.: Federal Circuit Finds Forum Selection Clause Does Not Bar IPR Proceedings Based on Contract Interpretation | Haug Partners LLP
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

United statesLos angeles cntyDexcom incUs courtAbbott diabetes care sales corpSarepta therapeutics incNippon shinyaku coAbbott diabetes care incUs district courtDiabetes careFederal circuitAbbott diabetes careAbbott diabetes care salesCovenant periodLicensed patentsWestern district

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average […]

New zealand generalNew zealandHans lennart rudolf wigzellVanguard group incNeedham companyCapital international investorsSarepta therapeutics company profileAvoro capital advisorsNorges bankSecurities exchange commissionWellington management groupSarepta therapeutics incRoyal bankCantor fitzgeraldSarepta therapeuticsGet free report

Research Analysts Offer Predictions for Sarepta Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) – Zacks Research lowered their Q2 2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($0.06) per share for the quarter, down from their prior estimate of […]

Ian michael estepanSecurities exchange commissionCantor fitzgeraldInvestment managementZacks researchPartners investment advisorySarepta therapeutics incSarepta therapeutics company profileSarepta therapeuticsFree reportSarepta therapeuticGet free reportCapital wealth advisorsCary street partners investment advisoryStreet partners investment advisoryDirector kathryn jean boor

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Net product revenues for the first quarter 2024 totaled $359.5 million, a 55% increase over the same quarter of the prior year ELEVIDYS net revenues for the quarter totaled $133.9.

United statesDoug ingramRoche ltdDrug administrationTrademark officeSarepta therapeutics incExchange commissionSarepta therapeuticsRecent developmentsPriority reviewBiologics license applicationThree months endedSafety informationSerious liver injuryPrecision genetic medicine engineUnited states patent

Sarepta Therapeutics (SRPT) Set to Announce Quarterly Earnings on Wednesday

Sarepta Therapeutics (SRPT) Set to Announce Quarterly Earnings on Wednesday
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ian michael estepanSarepta therapeutics incNeedham companySecurities exchange commissionSarepta therapeuticsGet free reportTherapeutics trading downMichael estepanExchange commissionDirector kathryn jean boorSarepta therapeutics daily